REFORM study: Reviewing Effects of Vildagliptin-Dapagliflozin FDC on HbA1c & Weight in Type 2 Diabetes Management - Video
|
Overview
The fixed-dose combination (FDC) of Vildagliptin 100mg SR and Dapagliflozin 10mg showed significant glycemic control, weight reduction, and favorable safety outcomes in managing Type 2 Diabetes (T2D) in a recent study published in the July 2024 edition of the Journal of Medicine and Healthcare has concluded.
This retrospective analysis evaluated data from 1587 T2D patients prescribed vildagliptin dapagliflozin FDC, with two follow-up visits over a six-month period. It included 1,587 records from 72 centers, with patients of an average age of 55.8 years. Patients were grouped by diabetes duration and baseline HbA1c levels (less than 7%, 7-8%, 8-9%, greater than or equal to 9%).
Some of the Key Findings of the study are:
1. Glycemic Control: After six months of therapy, patients experienced an average HbA1c reduction of 1.28%. Among those with baseline HbA1c greater than 7%, 67.2% achieved the target HbA1c of less than 7%. The most substantial improvement was observed in patients with HbA1c greater than or equal to 9%, who experienced a reduction of 2.0%, while reductions were 0.8% in the HbA1c 7–8% group and 1.1% in the HbA1c 8–9% group.
2. Weight Reduction: The highest weight reduction 4.9 kg was observed in those with baseline HbA1c ≥9%, with an overall average weight loss of 4.3 kg across all groups.
3. Safety Profile: The FDC was well-tolerated, with no major adverse events or episodes of hypoglycemia reported. No patient withdrawals were attributed to safety concerns. Vildagliptin 100mg SR + Dapagliflozin 10mg FDC showed to be an effective treatment for T2D, given its synergistic capacity to help achieve glycemic targets while offering benefits like weight reduction and improved liver enzymes.
Speakers
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751